Dr. Avani Jain

Consultant - Nuclear Medicine

MBBS, DNB (Nuclear Medicine), DipCBNC, FEBNM, FANMB

Industry Experience

10+ years in the field of Nuclear Medicine

Senior Registrar & Junior Consultant at Apollo Main Hospital, Chennai (May 2014- March 2018)

Consultant Nuclear Medicine & PET-CT at HCG Cancer Centre, Vadodara (April 2018- December 2022)

Consultant Nuclear Medicine & PET-CT at Baroda Imaging Centre, Vadodara (January 2023-April 2024)

Academic Details

• MBBS from PRAMUKHSWAMI MEDICAL COLLEGE KARAMSAD
• DNB (Nuclear Medicine) from Apollo Hospitals, Chennai.
• DipCBNC - Certification in Nuclear Cardiology by Alliance for Physician Certification and Advancement (APCA), US.
• FEBNM – Fellowship of European Board of Nuclear Medicine , Vienna
• FANMB – Fellowship of Asian Board of Nuclear Medicine, Yokohama, Japan

Expertise & Specialities

Prolific experience in PET-CT imaging for its various applications including Cancer imaging with novel radiopharmaceuticals (Ga-68 PSMA, Ga-68 DOTA, Ga-68 Exendin, Ga-68 FAPI, F18-DOPA & F18- Choline). Strong analytical skills for deriving accurate diagnoses in complex studies likely Neuro-PET & Cardiac-PET.

Skilled in all conventional Nuclear Medicine imaging procedures (renal, thyroid, bone scans, lymphoscintigraphy, gastrointestinal transit) with niche expertise in hepatobiliary scintigraphy & nuclear cardiac imaging.

Well-versed with radionuclide therapies including Radioactive I-131 therapy for thyrotoxicosis & adjuvant treatment in thyroid carcinoma, Lu-177 PSMA-Radioligand Therapy for metastatic castrationresistant prostate malignancies, Lu-177 Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors, Selective Internal Radiation Therapy (SIRT) –Transarterial Radioembolisation of hepatic malignancies with Y-90 microspheres.

Areas of Medical Interest

• Molecular imaging of cancers
• Infection & Inflammation
• Coronary artery disease
• Cardiac Sarcoidosis
• Neurodegeneration
• Neuroinflammation
• Targeted Radionuclide therapies

Career Highlights

Publications – She has multiple pub-med indexed publications in peer-reviewed national and international journals, of which notable ones are –

Jain AS, Pawaskar AS, Srivastava MK, Elangovan IM, Shelley S. Monoarticular carcinomatous knee joint arthritis as an initial presentation of cervical carcinoma. J Obstet Gynaecol Res. 2013 Oct;39(10):1488-91. doi: 10.1111/jog.12086. Epub 2013 Jul 15. PMID: 23855455

Jain AS, Simon S, Muthukrishnan I, Gambhir A, Patil S. Pericardial Synovial Sarcoma Followed Up With Contrast-Enhanced PET-CT. Clin Nucl Med. 2017 Apr;42(4):315-318. doi: 10.1097/RLU.0000000000001574. PMID: 28195904.

Jain A, Simon S, Elangovan I. (18)F-fluoro-deoxyglucose positron emission tomography-computed tomography in initial assessment and diagnosis of right atrial angiosarcoma with widespread visceral metastases: A rare case report and review of the literature. Indian J Nucl Med. 2015 Jan-Mar;30(1):51-4. doi: 10.4103/0972-3919.147541. PMID: 25589807; PMCID: PMC4290067.

Jain A, Srivastava MK, Pawaskar AS, Shelley S, Elangovan I, Jain H, Pandey S, Kalal S, Amalachandran J. Contrast-enhanced [18F] fluorodeoxyglucose-positron emission tomography-computed tomography as an initial imaging modality in patients presenting with metastatic malignancy of undefined primary origin. Indian J Nucl Med. 2015 Jul- Sep;30(3):213-20. doi: 10.4103/0972-3919.158529. PMID: 26170563; PMCID: PMC4479909.

Jain AS, Shelley S, Muthukrishnan I, Kalal S, Amalachandran J, Chandran S. Diagnostic importance of contrast-enhanced (18)F-fluorodeoxyglucose positron emission computed tomography in patients with tumor-induced osteomalacia: Our experience. Indian J Nucl Med. 2015 Jul- Sep;30(3):213-20. doi: 10.4103/0972-3919.158529. PMID: 26170563; PMCID: PMC4479909.

Jain AS, Simon S, Muthukrishnan I, Mohan AT, Balsubramaniam R. Standardization of "In-House fatty meal" methodology for cholescintigraphy. Indian J Nucl Med. 2015 Oct- Dec;30(4):303-8. doi: 10.4103/0972-3919.164021. PMID: 26430312; PMCID: PMC4579613.

She has multiple abstract presentations at various international and national conferences, the most notable ones are.

18F-FDG PET-CT as an initial imaging modality for evaluation of patients with metastasis of unknown site of primary malignancy; 25th Annual Congress of European Association of Nuclear Medicine – European Congress of Nuclear Medicine (EANM) Oct 2012, Milan, Italy.

Evolving role of contrast enhanced [F-18] FDG PET-CT in pyrexia of unknown origin in Solid Organ Transplant Recipients : Our initial experience; 12th Asia Oceania Congress of Nuclear Medicine Biology, Yokohama, October 2017.

Inhouse fatty meal cholescintigraphy in characterisation of dyspepsia symptom complex; Nuclear Medicine Update August 2015, Singapore

FDG PET-CT in carcinoma of unknown primary - Best paper presentation in 43rd Annual conference of Society of Nuclear Medicine India, Dec 2011, Chennai.

Diagnostic importance of contrast enhanced FDG PET-CT in patients with tumor induced phosphaturic osteomalacia; 67th Annual State IRIA Conference, Dec 2014, Chennai.